Gansu Longshenrongfa Pharmaceutical Industry CO.,LTD(300534.SZ)
No price history available.
Key financial summary
Financials in CNY| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | CNYm | 255 | 288 | 413 | 1,080 | 1,039 | 878 | N/A | N/A |
| Operating profit | CNYm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net profit | CNYm | 2 | -9 | 26 | 62 | 26 | 44 | N/A | N/A |
| EPS reported | CNY | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating cashflow per share | CNY | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Capex per share | CNY | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF per share | CNY | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Free cash flow | CNYm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt | CNYm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value equity | CNYm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value per share | CNY | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Number of shares | m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| DPS (TTM paid) | CNY | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Financial summary
Financials in CNY| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/B LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/S LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/FCF LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/EBITDA LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/Sales LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Earnings Yield LTM | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Quality | |||||||||
| ROE | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| ROIC | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Sales | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Growth and momentum | |||||||||
| EPS Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Sales Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Income Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating Profit Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend and capital structure | |||||||||
| Dividend Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Payout Ratio | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Debt | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Debt/EBITDA | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EBIT/Net interest | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/market cap | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/Equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross debt/equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
Gansu Longshenrongfa Pharmaceutical Industry Co.,Ltd operates as a pharmaceutical enterprise, focusing on the research, development, manufacturing, and commercialization of traditional Chinese medicines, health supplements, and active pharmaceutical ingredients (APIs). Its extensive product line includes therapeutic remedies such as Yuanhu Analgesic dropping pills, Qiwei Wenyang capsules, Maxing cough capsules, Shuxinning tablets, Panax notoginseng pills, Anti-inflammatory and gallbladder tablets, Children's Qingfei cough tablets, Pediatric Qinggan tablets, Suanzaoren oil dropping pills, Xiaoshuan Tongluo tablets, Xiaoyanlidan tablets, Compound Danshen tablets, Astragalus Angelica capsules, and berberine tannin films. Beyond its core manufacturing, the company is actively involved in the cultivation, procurement, processing, and distribution of Chinese medicinal raw materials. Its operations further encompass project investment and management, alongside the import, sale, logistics, and export of pharmaceutical goods. Established in 2002, Gansu Longshenrongfa Pharmaceutical Industry Co.,Ltd is headquartered in Lanzhou, China.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Gansu Longshenrongfa Pharmaceutical Industry CO.,LTD (300534.SZ)
No price history available.
Not enough data to calculate KvantraRank
Based on consensus from external analysts. Not Kvantra's opinion.
Gansu Longshenrongfa Pharmaceutical Industry Co.,Ltd operates as a pharmaceutical enterprise, focusing on the research, development, manufacturing, and commercialization of traditional Chinese medicines, health supplements, and active pharmaceutical ingredients (APIs). Its extensive product line includes therapeutic remedies such as Yuanhu Analgesic dropping pills, Qiwei Wenyang capsules, Maxing cough capsules, Shuxinning tablets, Panax notoginseng pills, Anti-inflammatory and gallbladder tablets, Children's Qingfei cough tablets, Pediatric Qinggan tablets, Suanzaoren oil dropping pills, Xiaoshuan Tongluo tablets, Xiaoyanlidan tablets, Compound Danshen tablets, Astragalus Angelica capsules, and berberine tannin films. Beyond its core manufacturing, the company is actively involved in the cultivation, procurement, processing, and distribution of Chinese medicinal raw materials. Its operations further encompass project investment and management, alongside the import, sale, logistics, and export of pharmaceutical goods. Established in 2002, Gansu Longshenrongfa Pharmaceutical Industry Co.,Ltd is headquartered in Lanzhou, China.